SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

MGC030

MGNX·MacroGenics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
If successful through all clinical phases, potential approval would likely be many years away (approximately 2029-2031 at the earliest), as the drug is just entering Phase 1 dose-escalation studies.
Why 2/10
MGC030 just entered Phase 1 (first patient dosed October 15, 2026) with no scheduled binary catalyst in the next 12 months; no PDUFA date, pivotal readout, or regulatory decision applies. The drug is one of several early-stage pipeline assets at a company whose value is driven primarily by MGC026.
Actionable Insight NEUTRAL

MGC030 is in very early-stage Phase 1 dose escalation with no interim data or binary catalyst on the calendar. Watch for any initial safety and pharmacokinetic data readouts, likely in late 2027 or 2028. The more impactful near-term catalyst for MGNX is the next MGC026 data update anticipated mid-2027. MGC030 alone is unlikely to move the stock meaningfully in the next 12 months.

Price Chart

Loading chart...

Executive Summary

MGC030 is an early-stage antibody-drug conjugate (ADC) from MacroGenics (MGNX) that targets an undisclosed antigen expressed on multiple solid tumor types. The company dosed the first patient in a Phase 1 study in October 2026, meaning the drug is at the very start of clinical development with no efficacy or safety data reported yet. MGC030 is one of several pipeline programs at MacroGenics, following behind the company's lead B7-H3 ADC MGC026 (which reported encouraging Phase 1 data at ESMO 2026). With a current stock price of $2.20, analyst mean price target of $8.00 (implying ~264% upside), and $288M in cash providing runway through 2028, MGC030 is a very early-stage, high-risk/high-reward pipeline asset that is unlikely to drive near-term stock movement on its own.

How It Works

MGC030 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy that works like a guided missile. It consists of an antibody (the 'guidance system') that binds to a specific protein found on the surface of solid tumor cells, linked to a potent chemotherapy drug (the 'warhead'). The antibody seeks out cancer cells, binds to them, and delivers the chemotherapy directly inside the cell, aiming to kill tumors while sparing healthy tissue. MacroGenics has not disclosed which specific protein (antigen) MGC030 targets.

Trial Status

First patient dosed October 15, 2026 in a Phase 1 dose-escalation study for advanced solid tumors. No interim data have been reported. The study is actively enrolling.

The Two-Sided Case

▲ Bull Case4
MGC030 is a novel antibody-drug conjugate (ADC) leveraging MacroGenics' proprietary ADC platform, which has shown encouraging data with the company's lead B7-H3 ADC MGC026 (27% best ORR in heavily pretreated SCCHN at ESMO 2026).
MacroGenics has $288M in cash with runway through 2028, providing ample funding to advance MGC030 through early-stage development without near-term dilution risk.
Analyst consensus skews bullish: 9 Buy/Strong Buy versus 5 Hold, with a mean price target of $8.00 (implying ~264% upside from the $2.20 close), and institutional accumulation was seen from BlackRock, FMR, and State Street in Q3.
The undisclosed tumor antigen target may represent a first-in-class opportunity if successfully validated, with a broad solid-tumor label potential.
▼ Bear Case5
MGC030 is at the very beginning of clinical development (first patient dosed October 2026) with no efficacy data at all, making it a high-risk, long-duration asset with many failure points ahead.
The target antigen is undisclosed, making independent assessment of the drug's competitive positioning impossible for investors.
MacroGenics has no approved revenue-generating drugs; total revenues for the 9 months ended Sep 30, 2026 were $58M, down from $67M in the prior-year period, and the company relies on its $288M cash pile (runway through 2028) to fund operations.
MGC030 is a minor/supporting pipeline asset behind the company's lead ADC MGC026, and its early stage means it contributes negligible valuation to the stock today.
Several institutional holders nearly exited in Q3 2026 (Walleye Capital -98.7%, Dimensional Fund Advisors -83.6%, Jane Street -79.4%), and the stock trades around $2.20, near the low end of its 52-week range of $1.32-$5.08.

Upcoming Catalysts

  • No scheduled catalysts for MGC030 in the next 12 months; initial Phase 1 dose-escalation data unlikely before late 2027 or 2028.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MacroGenics, Inc. PRESS-RELEASE MGNX ·Originating report

Sources · 5

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 sec.gov4 sec.gov5 msn.com